NCT02453789View on ClinicalTrials.gov

A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

December 31, 2017

Conditions
Cystic FibrosisBurkholderia Infection
Interventions
DRUG

Alginate oligosaccharide

Inhalation of dry powder for inhalation (DPI)

DRUG

Placebo

Trial Locations (2)

13353

Charité Universitätsmedizin Berlin, Berlin

81241

Pneumologische Praxis Pasing, Münich

Sponsors

Lead Sponsor

AlgiPharma AS
All Listed Sponsors
lead

AlgiPharma AS

INDUSTRY

NCT02453789 - A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection | Biotech Hunter | Biotech Hunter